박막 의약품 시장 : 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰, 예측(2026-2034년)

Growth Factors of thin film drugs Market

The global thin film drugs market was valued at USD 12.08 billion in 2025 and is projected to grow to USD 13.34 billion in 2026, reaching USD 29.74 billion by 2034, exhibiting a strong CAGR of 10.54% during the forecast period (2026-2034). The market is witnessing significant expansion due to the increasing demand for advanced drug delivery systems that offer convenience, rapid absorption, and improved patient compliance.

North America dominated the market in 2025, accounting for 35.36% share, supported by strong healthcare infrastructure, high awareness levels, and rapid adoption of innovative pharmaceutical technologies.

Market Overview

Thin film drug delivery is an innovative method of administering medication through dissolvable strips placed in the oral cavity or on the skin. These films dissolve quickly and deliver drugs directly into the bloodstream, making them highly effective for patients who face difficulty swallowing tablets or capsules.

The technology is gaining traction globally due to its fast-acting nature and ability to enhance bioavailability. Additionally, pharmaceutical companies are increasingly exploring this format to extend the lifecycle of existing drugs and improve patient experience.

During the COVID-19 pandemic, the market experienced temporary disruptions in research and development activities. However, recovery was swift, and the market regained momentum post-2021 due to increased manufacturing capabilities and renewed focus on innovative drug delivery solutions.

Market Trends

Growing Focus on Strategic Collaborations

One of the key trends shaping the market is the increasing number of mergers, acquisitions, and collaborations among pharmaceutical companies. These strategies are aimed at strengthening product pipelines and expanding technological capabilities.

Companies are investing in partnerships to accelerate the development of thin-film therapeutics, especially for complex diseases such as neurological and gastrointestinal disorders.

Market Growth Factors

1. Rising Investment in R&D

Continuous research and development activities are driving innovation in thin film drug delivery systems. Pharmaceutical companies are focusing on developing new formulations, including cannabis-based drugs and treatments for chronic diseases.

2. Increasing Geriatric Population

The growing elderly population is a major growth driver. Older patients often prefer easy-to-administer drug formats, boosting the adoption of thin film drugs for conditions such as Alzheimer's and Parkinson's disease.

3. Regulatory Approvals

Rising approvals for new thin film drug formulations are accelerating market expansion. These approvals validate the safety and effectiveness of this delivery method, encouraging wider adoption.

Restraining Factors

Limited Adoption in Emerging Economies

Despite strong growth potential, the market faces challenges due to limited penetration in developing countries such as India, Brazil, and China. High development costs and lack of funding restrict research activities in these regions.

Market Segmentation Analysis

By Drug Type

• Oral Thin Films (OTF) dominated the market with a 55.62% share in 2026, driven by ease of use and rapid drug absorption.
• Transdermal films are expected to grow steadily due to their application in pain management therapies.

By Disease Indication

• Schizophrenia is the leading segment, projected to generate USD 6.55 billion revenue by 2025 and account for 54.21% share in 2026.
• Migraine and opioid dependence segments are also witnessing increasing adoption.

By Distribution Channel

• Hospital pharmacies are expected to dominate with a 45.25% share in 2026, due to increased hospital-based prescriptions.
• Retail pharmacies continue to play a key role due to widespread availability of products.

Regional Analysis

North America

The region generated USD 4.27 billion in 2025 and is expected to reach USD 4.7 billion in 2026. Growth is driven by high prevalence of neurological disorders and strong adoption of advanced therapies.

Europe

Europe accounted for USD 3.22 billion in 2025 and is projected to reach USD 3.56 billion in 2026, supported by increasing R&D investments and government funding.

Asia Pacific

The market stood at USD 2.64 billion in 2025 and is projected to grow to USD 2.95 billion in 2026, driven by rising healthcare expenditure and awareness.

Latin America & Middle East & Africa

These regions are gradually expanding due to improving healthcare infrastructure and increased access to treatment options.

Key Companies

Major players operating in the market include:

• Pfizer, Inc.
• Novartis AG
• AbbVie Inc.
• Aquestive Therapeutics
• ZIM Laboratories Limited

These companies focus on product innovation, strategic collaborations, and expanding their global presence.

Conclusion

The thin film drugs market is poised for strong growth over the forecast period, driven by rising demand for patient-friendly drug delivery systems, increasing prevalence of chronic and neurological diseases, and continuous technological advancements. With the market projected to grow from USD 12.08 billion in 2025 to USD 29.74 billion by 2034, it presents significant opportunities for pharmaceutical companies and investors.

Although challenges such as high development costs and limited adoption in emerging economies persist, increasing R&D investments and regulatory approvals are expected to overcome these barriers. Overall, thin film drug delivery systems are set to revolutionize the pharmaceutical landscape by offering faster, safer, and more convenient treatment options.

Segmentation By Drug Type

• Oral Thin Film Drugs
• Transdermal Thin Film Drugs

By Disease Indication

• Schizophrenia
• Migraine
• Opioid Dependence
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Geography

• North America (By Drug Type, By Disease Indication, By Distribution Channel, By Country)
  • USA (By Drug Type)
  • Canada (By Drug Type)
• Europe (By Drug Type, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • UK (By Drug Type)
  • Germany (By Drug Type)
  • France (By Drug Type)
  • Italy (By Drug Type)
  • Spain (By Drug Type)
  • Scandinavia (By Drug Type)
  • Rest of Europe (By Drug Type)
• Asia Pacific (By Drug Type, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Japan (By Drug Type)
  • China (By Drug Type)
  • India (By Drug Type)
  • Australia (By Drug Type)
  • Southeast Asia (By Drug Type)
  • Rest of Asia Pacific (By Drug Type)
• Latin America (By Drug Type, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • Brazil (By Drug Type)
  • Mexico (By Drug Type)
  • Rest of Latin America (By Drug Type)
• Middle East & Africa (By Drug Type, By Disease Indication, By Distribution Channel, By Country/Sub-Region)
  • GCC (By Drug Type)
  • South Africa (By Drug Type)
  • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Schizophrenia, By Key Countries/Regions, 2025
• 4.2. Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
• 4.3. Overview of Regulatory Scenario, By Key Countries/ Regions
• 4.4. Impact of COVID-19 on the Market

5. Global Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Type
  • 5.1.1. Oral Thin Film Drugs
  • 5.1.2. Transdermal Thin Film Drugs
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Schizophrenia
  • 5.2.2. Migraine
  • 5.2.3. Opioid Dependence
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Retail Pharmacy
  • 5.3.2. Hospital Pharmacy
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Type
  • 6.1.1. Oral Thin Film Drugs
  • 6.1.2. Transdermal Thin Film Drugs
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Schizophrenia
  • 6.2.2. Migraine
  • 6.2.3. Opioid Dependence
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Retail Pharmacy
  • 6.3.2. Hospital Pharmacy
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Drug Type
  • 6.4.2. Canada
    • 6.4.2.1. By Drug Type

7. Europe Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Type
  • 7.1.1. Oral Thin Film Drugs
  • 7.1.2. Transdermal Thin Film Drugs
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Schizophrenia
  • 7.2.2. Migraine
  • 7.2.3. Opioid Dependence
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Retail Pharmacy
  • 7.3.2. Hospital Pharmacy
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.4.1. U.K.
    • 7.4.1.1. By Drug Type
  • 7.4.2. Germany
    • 7.4.2.1. By Drug Type
  • 7.4.3. France
    • 7.4.3.1. By Drug Type
  • 7.4.4. Spain
    • 7.4.4.1. By Drug Type
  • 7.4.5. Italy
    • 7.4.5.1. By Drug Type
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Drug Type
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Drug Type

8. Asia Pacific Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Type
  • 8.1.1. Oral Thin Film Drugs
  • 8.1.2. Transdermal Thin Film Drugs
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Schizophrenia
  • 8.2.2. Migraine
  • 8.2.3. Opioid Dependence
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Retail Pharmacy
  • 8.3.2. Hospital Pharmacy
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.4.1. Japan
    • 8.4.1.1. By Drug Type
  • 8.4.2. China
    • 8.4.2.1. By Drug Type
  • 8.4.3. India
    • 8.4.3.1. By Drug Type
  • 8.4.4. Australia
    • 8.4.4.1. By Drug Type
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Drug Type
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Drug Type

9. Latin America Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Type
  • 9.1.1. Oral Thin Film Drugs
  • 9.1.2. Transdermal Thin Film Drugs
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Schizophrenia
  • 9.2.2. Migraine
  • 9.2.3. Opioid Dependence
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Retail Pharmacy
  • 9.3.2. Hospital Pharmacy
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.4.1. Brazil
    • 9.4.1.1. By Drug Type
  • 9.4.2. Mexico
    • 9.4.2.1. By Drug Type
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Drug Type

10. Middle East & Africa Thin Film Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Type
  • 10.1.1. Oral Thin Film Drugs
  • 10.1.2. Transdermal Thin Film Drugs
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Schizophrenia
  • 10.2.2. Migraine
  • 10.2.3. Opioid Dependence
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Retail Pharmacy
  • 10.3.2. Hospital Pharmacy
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.4.1. GCC Countries
    • 10.4.1.1. By Drug Type
  • 10.4.2. South Africa
    • 10.4.2.1. By Drug Type
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Drug Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer, Inc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. ZIM Laboratories Limited
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Novartis AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Aquestive Therapeutics
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Sumitomo Dainippon Pharma Co.Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. IntelGenx Corp
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Bionxt Solutions
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. AbbVie Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)